Combination transurethral resection, systemic chemotherapy, and pelvic radiotherapy for invasive (T2-T4) bladder cancer unsuitable for cystectomy: A phase I/II Southwestern Oncology Group study

Urology

Volumn 47, Issue 5, 1996, Pages 652-657

  Einstein Jr , Albert B ^a   Wolf, Michael ^b   Halliday, Karen R ^b   Miller, Gary J ^b   Hafermann, Mark ^b   Lowe, Bruce A ^b   Meyers, Frederick J ^b   Leimert, J Thomas ^b   Crawford, E David ^b  

^a Southwest Oncology Group   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; LORAZEPAM; MAGNESIUM CHLORIDE; MANNITOL; METHOTREXATE; METOCLOPRAMIDE; POTASSIUM CHLORIDE; PROCHLORPERAZINE; VINBLASTINE;

ADULT; AGED; ARTICLE; BIOPSY; BLADDER CANCER; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CYSTOSCOPY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; VOMITING;

EID: 0029977496     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00019-2     Document Type: Article

References (16)

1. Pearse HD, Pappas JT, and Hodges CV: Radical cystectomy for bladder cancer: 10-year survival. J Urol 109: 623-624, 1973.
2. Skinner DG: Current perspectives in the management of high grade invasive bladder cancer. Cancer 45: 1866-1874, 1980.
3. Herr HW: Conservative management of muscle-infiltrating bladder cancer: prospective experience. J Urol 138: 1162-1163, 1987.
4. Rider WD, and Evans DH: Radiotherapy in the treatment of recurrent bladder cancer. Br J Urol 48: 595-601, 1976.
5. Caldwell WL: Radiotherapy: definitive, integrated and palliative therapy. Urol Clin North Am 3: 129-148, 1976.
6. Bloom HJ, Hendry WF, Wallace DM, and Skeet RG: Treatment of T3 bladder cancer: controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy. Br J Urol 54: 136-151, 1982.
7. Goffinet DR, Schneider MJ, Glatstein EJ, Ludwig H, Ray GR, Dunnick NR, and Bagshaw MA: Bladder cancer: results in radiation therapy in 384 patients. Radiology 117: 149-153, 1975.
8. Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani PC, et al: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133: 403-407, 1985.
9. Logothetis CJ, Samuels ML, Ogden S, Dexeus FH, Swanson D, Johnson DE, and von Eschenbach A: Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases. J Urol 134: 460-464, 1985.
10. Harker WG, Meyers FJ, Freiha FS, Palmer JM, Shortliffe LD, Hannigan JF, McWhirter KM, and Torti FM: Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group Study. J Clin Oncol 3: 1463-1470, 1985.
11. Stoter G, Splinter TA, Child JA, Fosså SD, Denis L, Van Oosterom AT, de Pauw M, and Sylvester R: Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J Urol 137: 663-667, 1987.
12. Shipley WU, Prout GR Jr, Einstein AB, Coombs LJ, Wajsman Z, Soloway MS, Englander L, Barton BA, and Hafermann MD: Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA 258: 931-935, 1987.
13. Beahrs OH, Henson DE, Hutter RVP, Myers MH: Manual for Staging of Cancer, 3rd ed. Philadelphia, JB Lippincott, 1988, pp 193-196.
14. Green S, and Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10: 239-253, 1992.
15. Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, and Efird JT: Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 329: 1377-1382, 1993.
16. Einstein AB Jr, Shipley W, Coombs J. Cummings KB, Soloway MS, and Hawkins I: Cisplatin as adjunctive treatment for invasive bladder carcinoma: tolerance and toxicities. Urology 23 (suppl): 110-117, 1984.